{"id":46878,"date":"2022-08-03T13:02:06","date_gmt":"2022-08-03T11:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/"},"modified":"2022-08-03T13:02:06","modified_gmt":"2022-08-03T11:02:06","slug":"abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/","title":{"rendered":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients"},"content":{"rendered":"
\n

\nAtlas’ stealth-stage company will leverage AbCellera\u2019s technology to start and advance new drug programs with enhanced speed and capital efficiency<\/i>\n<\/p>\n

<\/a><\/p>\n

VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL<\/a>—AbCellera<\/a> (Nasdaq: ABCL) and Atlas Venture<\/a> announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas\u2019 proven track record in forming innovative biotechnology companies and AbCellera\u2019s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster.\n<\/p>\n

\n“AbCellera\u2019s clinically validated platform lets us start discovery in a virtualized model that aligns well with our capital efficient investment strategy,\u201d said Steven Robinette, Ph.D., Venture Partner at Atlas Venture. \u201cThis partnership supports our approach to value creation by allowing us to focus on building companies that aim to deliver impactful medicines to patients.\u201d\n<\/p>\n

\n\u201cAtlas has proven expertise in finding and transforming innovative scientific research into exciting new biotechs,\u201d said Carl Hansen, Ph.D., CEO and President of AbCellera. \u201cBy eliminating their need to build internal antibody discovery capabilities at inception, we provide newly launched biotech ventures with a competitive advantage that empowers them to move faster and increase their probability of success. We look forward to working alongside Atlas\u2019 entrepreneurs to unlock their breakthrough science and create new therapies for patients in need.\u201d\n<\/p>\n

\nUnder the terms of the agreement, Atlas\u2019 portfolio company will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and will be eligible to receive clinical and commercial milestone payments and royalties on net sales of products.\n<\/p>\n

\nAbout Atlas Venture<\/b>\n<\/p>\n

\nAtlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com<\/a>.\n<\/p>\n

\nAbout AbCellera Biologics Inc.<\/b>\n<\/p>\n

\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com<\/a>.\n<\/p>\n

\nAbCellera Forward-looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\n<\/p>\n

\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\n<\/p>\n

\nSource: AbCellera Biologics Inc.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAbCellera<\/b>
Media: Jessica Yingling, Ph.D.; media@abcellera.com<\/a>, +1(236)521-6774
\n
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com<\/a>, +1(604)559-9005
\n
Investor Relations: Melanie Solomon; ir@abcellera.com<\/a>, +1(778)729-9116<\/p>\n

Atlas<\/b>
Kristen Margeson, Vice President of Investor Relations and Marketing; lifesciences@atlasventure.com<\/a>, +1(857)201-2700\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Atlas’ stealth-stage company will leverage AbCellera\u2019s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46878","6":"format-standard","7":"category-industry"},"yoast_head":"\nAbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Atlas’ stealth-stage company will leverage AbCellera\u2019s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-03T11:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients\",\"datePublished\":\"2022-08-03T11:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/\"},\"wordCount\":787,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005076\\\/en\\\/705128\\\/21\\\/AbCellera_Full_Colour_RGB_1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/\",\"name\":\"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005076\\\/en\\\/705128\\\/21\\\/AbCellera_Full_Colour_RGB_1.jpg\",\"datePublished\":\"2022-08-03T11:02:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005076\\\/en\\\/705128\\\/21\\\/AbCellera_Full_Colour_RGB_1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005076\\\/en\\\/705128\\\/21\\\/AbCellera_Full_Colour_RGB_1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend","og_description":"Atlas’ stealth-stage company will leverage AbCellera\u2019s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-03T11:02:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients","datePublished":"2022-08-03T11:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/"},"wordCount":787,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/","url":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/","name":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg","datePublished":"2022-08-03T11:02:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220803005076\/en\/705128\/21\/AbCellera_Full_Colour_RGB_1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/abcellera-and-atlas-venture-collaborate-to-empower-the-development-of-impactful-medicines-for-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46878"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46878\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}